Table 1.
Donor characteristics
| HC N = 247 |
AAb− N = 343 |
AAb1 + N = 208 |
AAb ≥ 2 + N = 208 |
T1Dnew N = 86 |
|
|---|---|---|---|---|---|
|
Age (years), median (range) |
16.97 (1.45–48.08) |
12.78 (1.11–46.03) |
18.06 (3.31–51.04) |
15.53 (4.32–45.56) |
13.39 (3.89–47.62) |
| Sex | |||||
| Female, n(%) | 116 (46.96%) | 191 (55.69%) | 101 (48.56%) | 106 (50.96%) | 35 (40.7%) |
| Male, n(%) | 131 (53.04%) | 152 (44.31%) | 107 (51.44%) | 102 (49.04%) | 51 (59.3%) |
| Number of Autoantibodies | n/a | ||||
| 0, n(%) | 343 (100%) | 1 (1.16%) | |||
| 1, n(%) | 208 (100%) | 12 (13.95%) | |||
| 2, n(%) | 91 (43.75%) | 15 (17.44%) | |||
| 3, n(%) | 74 (35.58%) | 38 (44.19%) | |||
| 4, n(%) | 38 (18.27%) | 20 (23.26%) | |||
| 5, n(%) | 5 (2.40%) | 0 | |||
| Type of autoantibody | n/a | ||||
| GAD65, n(%) | 167 (80.29%) | 197 (94.71%) | 72 (83.72%) | ||
| ZnT8, n(%) | 0 | 133 (63.94%) | 67 (77.91%) | ||
| IA2, n(%) | 6 (2.88%) | 70 (33.65%) | 54 (62.79%) | ||
| ICA, n(%) | 1 (0.48%) | 110 (52.88%) | 0 | ||
| IAA, n(%) | 33 (15.87%) | 71 (34.13%) | 43 (50%) | ||
| Pancreatic Amylase (U/L) | 25 (5–111) | 22 (4–93) | 23 (2–85) | 23 (0–93) | 16.5 (7–128) |
| Lipase (U/L) | 26 (11–153) | 27 (12–183) | 26 (9–81) | 24 (9–83) | 23 (12–350) |
|
Fasting c-peptide, median (ng/ml) |
n/a |
N = 64 1.61(0.595–3.695) |
N = 159 1.55(0.435–4.35) |
N = 188 1.455(0.375–3.25) |
N = 79 0.41(0–2.8) |
| HLA (DR3 or DR4), n(%) | n/a |
N = 97 67 (69.07%) |
N = 206 136 (66.02%) |
N = 201 153 (76.12%) |
n/a |
All characteristics are shown for the total 1092 observations (732 subjects and 598 families, range number of observations per subject = 1–13). HC, Healthy controls; AAb−, Autoantibody negative; AAb1 + , Positive for 1 islet autoantibody; AAb ≥ 2 + , Positive for 2 or more islet autoantibodies; T1Dnew, New onset type 1 diabetes patients. Data are presented as absolute %, mean ± SD, or median (first quartile, third quartile)